India’s Union Budget 2026 proposes a ₹10,000 crore BioPharma Shakti initiative aimed at strengthening domestic pharmaceutical innovation, manufacturing, and resilience.
India is one of the world’s largest suppliers of generic medicines. What it has struggled with is moving up the value chain — into drug discovery, complex biologics, and advanced therapeutics.
The India’s Union Budget proposed BioPharma Shakti initiative, with an outlay of ₹10,000 crore, is designed to change that equation.
Why BioPharma Shakti matters
The pandemic exposed vulnerabilities in global pharmaceutical supply chains, particularly around active pharmaceutical ingredients (APIs) and specialty drugs.
BioPharma Shakti aims to:
- Reduce import dependence
- Support indigenous R&D
- Strengthen advanced manufacturing
- Improve health security
It reflects a broader rethinking of pharmaceuticals as strategic infrastructure, not just an export industry.
From volume to value
India’s pharma sector has historically competed on cost and scale. Innovation-led pharma requires different capabilities:
- Long-term capital
- Regulatory sophistication
- Academic-industry collaboration
Budget 2026’s approach suggests a willingness to fund patient capital — a prerequisite for biopharma success.
Risks remain executional
Drug innovation timelines are long and uncertain. Returns are uneven.
The initiative’s impact will depend on:
- Transparent allocation mechanisms
- Integration with existing research institutions
- Regulatory predictability
BioPharma Shakti is a statement of intent. Whether it becomes a platform or a programme will depend on follow-through.
